Submission of Annual Secretarial Compliance Report for the financial year ended 31st March 2025.
BIOFILCHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biofil Chemicals & Pharmaceuticals filed its Annual Secretarial Compliance Report for FY 2024-25 with BSE and NSE on 27th May 2025, prepared by L N Joshi and Co., Practicing Company Secretaries. The main compliance flag is a delay in appointing a Company Secretary & Compliance Officer — the position remained vacant from 17th December 2024 to 18th April 2025, exceeding SEBI's 3-month limit under Regulation 6(1) and (1A) of LODR. The company attributed the delay to difficulty finding a qualified candidate and the unforeseen demise of its Chairman, and stated it is actively seeking a replacement. All other major compliance areas — Secretarial Standards, board policies, website, related party transactions, insider trading, director disqualifications, and performance evaluation — were reported as compliant. A prior-year observation about non-functional website and outdated content has since been addressed.
No serious action was taken by BSE for the delayed Company Secretary appointment, so the immediate regulatory risk is low, but investors should note the prolonged governance gap. Overall, the company appears broadly compliant with SEBI listing requirements, with no material red flags for shareholders.